Schizophrenia Research
Volume 93, Issue 1 , Pages 90-98, July 2007

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis

  • Martin Strassnig

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, United States
  • ,
  • Jean Miewald

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, United States
  • ,
  • Matcheri Keshavan

      Affiliations

    • Department of Psychiatry, Wayne State University, Detroit, MI, United States
  • ,
  • Rohan Ganguli

      Affiliations

    • Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 412 246 5006; fax: +1 412 246 5007.

Received 20 November 2006; received in revised form 6 February 2007; accepted 12 February 2007. published online 10 May 2007.

Abstract 

Background

Various antipsychotics are associated with body weight gain. However, most study samples include high proportions of patients with chronic schizophrenia. We examined neuroleptic-induced weight gain in drug-naïve first-episode psychotic patients to limit confounding variables such as multiple past medication trials, history of partial adherence; or poor diet and a sedentary lifestyle, associated with chronic mental illness.

Methods

Newly diagnosed first-episode psychosis patients treated with antipsychotic medication, a small group of patients not receiving antipsychotics, and healthy comparisons were followed for one year. Body weight differences and proportions of subjects with more than 7% weight gain were calculated. The effects of concomitant psychotropic medication on weight gain were explored.

Results

Ninety-eight first-episode psychotics patient and 30 healthy controls were examined. Patients receiving neuroleptics gained significantly more weight than healthy controls (p=0.002). Olanzapine (91% gained >7%) increased body weight by 37.3±27.7 lb, followed by risperidone (51%; +16.6±22) and haloperidol (47%; +9±12), and perphenazine (10%; +3.4±6). Younger patients (r=0.24, p=0.02) and patients with more negative symptoms at baseline (SANS global; r=0.22, p=0.04) gained more weight. A greater number of co-medications per patient, and co-prescription of antidepressants significantly and independently increased antipsychotic-associated weight gain.

Discussion

The results confirm substantial and clinically significant weight gain introduced by antipsychotic treatment in drug-naïve first-episode psychotic patients, and identify several treatment-associated risk factors for weight gain. The magnitude of weight gain induced highlights potential health risks and points to the need for preventive measures such as behavioral weight control programs along with the initiation of pharmacotherapy.

Keywords: Weight gain, Schizophrenia, First-episode psychosis, Antipsychotics, Antidepressants, Weight gain prevention, Obesity, Predictors

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0920-9964(07)00099-0

doi:10.1016/j.schres.2007.02.024

Schizophrenia Research
Volume 93, Issue 1 , Pages 90-98, July 2007